Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.45 |
| ▸ | CES1 | P23141 | 5/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26771499 | 0.83 | CES2 (0.50) | CES2CES1MAOBMAOAPKM | |
| SCHEMBL1192063 | 0.83 | CES2 (0.45) | CES2CES1SMN1; SMN2TSHR | |
| SCHEMBL23112646 | 0.83 | HPGD (0.41) | CES2CES1MAOBMAOASMN1; SMN2 | |
| SCHEMBL29775631 | 0.82 | CES2 (0.67) | CES2CES1MAOBMAOAPKM | |
| SCHEMBL671906 | 0.82 | CES2 (0.67) | CES2CES1MAOBMAOAPKM | |
| SCHEMBL4622385 | 0.81 | ALDH1A1 (0.47) | CES2CES1MAOBMAOASMN1; SMN2 | |
| SCHEMBL26103998 | 0.81 | MAPT (0.45) | CES2CES1MAOBMAOASMN1; SMN2 | |
| SCHEMBL5488010 | 0.81 | MAPT (0.43) | MAOBMAOASMN1; SMN2KMT2AESR1 | |
| SCHEMBL8429426 | 0.79 | HPGD (0.42) | MAOBMAOATSHR | |
| SCHEMBL31690101 | 0.79 | SMN1; SMN2 (0.33) | CES2CES1MAOBMAOASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458173-B2 | Amides of 2-amino-4-arylthiazole compounds and their salts | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-10-04 | — | — | US | disclosed |
| US-20150111038-A1 | AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-23 | — | — | US | disclosed |
| US-7915418-B2 | Intermediates and process for the production of optically active quinolonecarboxylic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1622912-B1 | 2-ALKYNYL-AND 2-ALKENYL-PYRAZOLO- [4,3-E ] -1,2,4-TRIAZOLO- [1,5-C] -PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1514864-B1 | Difluoralkyl aromatic compounds | SALTIGO GMBH (DE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1514864-A2 | Difluoralkyl aromatic compounds | Bayer Chemicals AG (DE) | 2005-03-16 | — | — | EP | disclosed |
| US-20050054733-A1 | Difluoroalkylaromatics | LANXESS DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-4870182-A | 4-Hydroxy-quinoline-3-carboxylic | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-26 | — | — | US | disclosed |
| US-4804760-A | Process for the preparation of 4-hydroxy-quinoline-3-carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1989-02-14 | — | — | US | disclosed |
| EP-0245690-A1 | Process for the preparation of 4-hydroxy-quinoline-3-carboxylic acids | BAYER AG (DE) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | CES2 1479/4885CES1 2126/4885MAOB 313/4885 |
| US-20150111038-A1 | AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS | AADAC, ABL2, ABL1 | CES2 2844/4885CES1 4296/4885MAOB 1324/4885 |
| US-20050054733-A1 | Difluoroalkylaromatics | NQO1, TYR, FLI1 | CES2 141/4885CES1 961/4885MAOB 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.